Middle-term outcomes in renal transplant recipients with COVID-19: a national, multicenter, controlled study

Basit Öğe Kaydı
dc.authoridGul, Cuma/0000-0003-2467-9356
dc.authoridkoyuncu, sumeyra/0000-0002-1159-5818
dc.authoridBakirdogen, Serkan/0000-0002-3448-0490
dc.authoridÖzer, Hakan/0000-0001-9174-0351
dc.authoridSahin, Idris/0000-0002-8683-3737
dc.authoridDheir, Hamad/0000-0002-3569-6269
dc.authoridAri Bakir, Elif/0000-0001-9208-7972
dc.authorwosidGul, Cuma/A-7063-2018
dc.authorwosidErken, Ertugrul/P-4517-2015
dc.authorwosidkoyuncu, sumeyra/HOH-4247-2023
dc.authorwosidBakirdogen, Serkan/ABI-3906-2020
dc.authorwosidÖzer, Hakan/HKN-9433-2023
dc.authorwosidSahin, Idris/AAS-4390-2020
dc.authorwosidEser, Zeynep/HZI-0576-2023
dc.contributor.authorOto, Ozgur Akin
dc.contributor.authorOzturk, Savas
dc.contributor.authorArici, Mustafa
dc.contributor.authorVelioglu, Arzu
dc.contributor.authorDursun, Belda
dc.contributor.authorGuller, Nurana
dc.contributor.authorSahin, Idris
dc.date.accessioned2024-06-12T10:58:45Z
dc.date.available2024-06-12T10:58:45Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground In this study, we evaluated 3-month clinical outcomes of kidney transplant recipients (KTR) recovering from COVID-19 and compared them with a control group. Method The primary endpoint was death in the third month. Secondary endpoints were ongoing respiratory symptoms, need for home oxygen therapy, rehospitalization for any reason, lower respiratory tract infection, urinary tract infection, biopsy-proven acute rejection, venous/arterial thromboembolic event, cytomegalovirus (CMV) infection/disease and BK viruria/viremia at 3 months. Results A total of 944 KTR from 29 different centers were included in this study (523 patients in the COVID-19 group; 421 patients in the control group). The mean age was 46 +/- 12 years (interquartile range 37-55) and 532 (56.4%) of them were male. Total number of deaths was 8 [7 (1.3%) in COVID-19 group, 1 (0.2%) in control group; P = 0.082]. The proportion of patients with ongoing respiratory symptoms [43 (8.2%) versus 4 (1.0%); P Conclusion The prevalence of ongoing respiratory symptoms increased in the first 3 months post-COVID in KTRs who have recovered from COVID-19, but mortality was not significantly different.en_US
dc.identifier.doi10.1093/ckj/sfac045
dc.identifier.endpage1006en_US
dc.identifier.issn2048-8505
dc.identifier.issn2048-8513
dc.identifier.issue5en_US
dc.identifier.pmid35498893en_US
dc.identifier.scopus2-s2.0-85142620316en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage999en_US
dc.identifier.urihttps://doi.org/10.1093/ckj/sfac045
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20181
dc.identifier.volume15en_US
dc.identifier.wosWOS:000768374700001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofClinical Kidney Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectKidney Transplantationen_US
dc.subjectMortalityen_US
dc.subjectOutcomeen_US
dc.subjectRegistryen_US
dc.titleMiddle-term outcomes in renal transplant recipients with COVID-19: a national, multicenter, controlled studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu